A Multicenter, Open-label, Phase 2 Study of Intratumoral CMP-001 in Combination With Intravenous Nivolumab in Subjects With Refractory Unresectable or Metastatic Melanoma
CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma
Sponsor: Checkmate Pharmaceuticals, Inc
Enrolling: Male and Female Patients
IRB Number: AAAT3262
U.S. Govt. ID: NCT04698187
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to determine the safety and efficacy of CMP-001 when given in combination with nivolumab for patients with unresectable (not capable of being surgically removed) or metastatic (cancer spreads to a different body part from where it started) melanoma. CMP-001 will be given as an injection into the tumor and nivolumab will be given intravenously (into the vein). The study will collect certain lab tests in your blood and/or tumor changes while on CMP-001 plus nivolumab therapy combination so we can better understand how the drug is working.
This study is closed
Benjamin Izar, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Do you have a confirmed diagnosis of melanoma? Yes No
Are you able and willing to provide informed consent and follow study instructions? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator